TriSalus Life Sciences, Inc. (TLSI) - Dilution Analysis

10-Q filing | 61.4M shares outstanding

S-3 filing: TriSalus Life Sciences, Inc. may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase Common Stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $150 million.

10-Q filing | 49.9M shares outstanding

8-K filing: TriSalus Life Sciences, Inc. announced the commencement of an exchange offer to exchange shares of common stock for preferred stock and a solicitation of consents from holders of the outstanding shares of Preferred Stock to amend the Certificate of Designations.

S-3 filing: This is an S-3 filing for shares of common stock offered by the Selling Stockholders.

10-Q filing | 37.8M shares outstanding

8-K filing: TriSalus Life Sciences, Inc. entered into a securities purchase agreement to issue and sell 5,500,000 shares of common stock at $4.00 per share in a private placement, anticipating gross proceeds of $22.0 million. ($22.0M proceeds)

S-3 filing: This prospectus relates to the offer and sale of up to 251,885 shares of common stock by selling stockholders.

S-3 filing: This prospectus relates to the offer and sale, from time to time, by the selling securityholders of up to 91,263 shares of our common stock issuable upon exercise of warrants.

10-K filing | 32.3M shares outstanding

10-Q filing | 30.5M shares outstanding

S-3 filing: TriSalus Life Sciences, Inc. is registering the resale of 10,587,582 shares of Common Stock by the Selling Securityholders.

POS AM filing: This prospectus relates to the offer and sale, from time to time, by the selling securityholder of up to 5,859,375 shares of our common stock, which is the number of shares of Common Stock that we may, at our discretion, elect to issue and sell to YA II PN, Ltd., pursuant to the Standby Equity Purchase Agreement, dated October 2, 2023.

POS AM filing: This prospectus relates to the issuance by us of an aggregate of up to 13,215,112 shares of our common stock issuable upon the exercise of warrants, the offer and sale by the Selling Securityholders of up to 36,772,040 shares of Common Stock, and up to 5,933,333 warrants

POS AM filing: This prospectus relates to the offer and sale, from time to time, by the selling securityholders identified in this prospectus of up to 130,805 shares of our common stock issuable upon exercise of the warrant granted to OrbiMed in connection with the credit agreement dated April 30, 2024.

10-Q filing | 29.3M shares outstanding

8-K filing: TriSalus Life Sciences, Inc. closed its offer to exchange warrants for 2,110,366 shares of common stock and completed the related consent solicitation.

8-K filing: TriSalus Life Sciences received the requisite approval to amend the warrant agreement for Public Warrants, allowing the company to convert each outstanding Public Warrant into 0.27 shares of Common Stock. The offer to exchange outstanding warrants expired on June 25, 2024, with 6,533,614 Public Warrants and 504,685 Private Placement Warrants validly tendered.

S-1 filing: This prospectus relates to the offer and sale, from time to time, by the selling securityholder identified in this prospectus (the "Selling Securityholder"), or its permitted transferees, of up to 130,805 shares of our common stock, $0.0001 par value per share ("Common Stock"), issuable upon exercise of the warrant (the "Initial OrbiMed Warrant") granted to OrbiMed Royalty & Credit Opportunities IV, LP ("OrbiMed") in connection with the credit agreement dated April 30, 2024.

8-K filing: TriSalus Life Sciences, Inc. commenced an offer to exchange outstanding warrants for common stock and a solicitation of consents to amend the warrant agreement, offering up to 4,264,532 shares of common stock.

10-Q filing | 27.2M shares outstanding

8-K filing: TriSalus Life Sciences, Inc. entered into a Credit Agreement providing for a $50 million senior secured credit facility and issued a warrant to purchase 130,805 shares of common stock to OrbiMed Royalty & Credit Opportunities IV, LP.

POS AM filing: This prospectus relates to the offer and sale of up to 5,859,375 shares of our common stock to YA II PN, Ltd. pursuant to a Standby Equity Purchase Agreement for up to $30.0 million.

POS AM filing: This POS AM filing registers the resale of common stock and warrants by selling securityholders, the issuance of common stock upon conversion of preferred stock, the potential issuance of shares under an equity incentive plan and employee stock purchase plan, and the potential issuance of shares to Yorkville under a SEPA.

10-K filing | 26.8M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 5,859,375 shares of common stock by the selling securityholder, which the company may elect to issue and sell to YA II PN, Ltd. (Yorkville) under the Standby Equity Purchase Agreement (SEPA). The company may sell up to $30.0 million of shares to Yorkville, subject to certain conditions.

S-1/A filing: This S-1/A filing registers for resale shares of common stock and warrants by selling securityholders, as well as shares of common stock issuable upon exercise of warrants.

10-Q filing | 26.3M shares outstanding

S-1/A filing: This S-1/A filing registers the issuance of common stock upon the exercise of warrants and the resale of common stock and warrants by selling securityholders.

S-1/A filing: This S-1/A filing registers the issuance of up to 14,266,605 shares of common stock issuable upon exercise of warrants and the resale of up to 52,536,549 shares of common stock and 5,933,333 warrants by selling securityholders.

S-1 filing: This S-1 filing registers the issuance of common stock upon exercise of warrants and resale of common stock and warrants by selling securityholders.

8-K filing: TriSalus Life Sciences 8-K filing on August 16, 2023, details the completion of a business combination, including unregistered sales of equity securities through the conversion of a convertible note into warrants, and modifications to the rights of security holders through the filing of a Certificate of Incorporation and Certificate of Designations for Series A Convertible Preferred Stock.

8-K filing: Holders of 890,499 shares of Class A Common Stock elected to redeem their shares for cash at approximately $10.58 per share, totaling approximately $9.42 million, in connection with a business combination. ($9.42M proceeds)

10-Q filing | 6.3M shares outstanding

8-K filing: MedTech Acquisition Corporation amended its Merger Agreement with TriSalus Life Sciences and entered into Additional Subscription Agreements for Series A Convertible Preferred Stock. ($40.15M proceeds)

8-K filing: MedTech Acquisition Corporation issued 6,249,999 shares of Class A common stock to MedTech Acquisition Sponsor LLC upon conversion of an equal number of Class B common stock.

8-K filing: MedTech Acquisition Corporation entered into subscription agreements with certain investors to purchase 1,785,502 shares of Series A Convertible Preferred Stock at $10.00 per share, resulting in gross proceeds of $17,855,020, with the closing of the purchase and sale occurring concurrently with the closing of the Business Combination. ($17.86M proceeds)

10-Q filing | 6.3M shares outstanding

10-K filing | 6.3M shares outstanding

8-K filing: MedTech Acquisition Corporation entered into a Merger Agreement with TriSalus Life Sciences, Inc., where Merger Sub will merge with TriSalus, with TriSalus surviving as a wholly-owned subsidiary of MTAC; the aggregate consideration payable to TriSalus stockholders is $220,000,000 in shares of MTAC common stock valued at $10.00 per share. ($220.0M proceeds)

10-Q filing | 6.3M shares outstanding

10-Q filing | 6.3M shares outstanding

10-Q filing | 6.3M shares outstanding

10-K filing | 6.3M shares outstanding

10-Q filing | 6.3M shares outstanding

10-Q filing | 6.3M shares outstanding

10-Q filing | 6.3M shares outstanding

8-K filing: MedTech Acquisition Corporation consummated its initial public offering of 25,000,000 units at $10.00 per Unit, generating gross proceeds of $250,000,000. The holders of the Units may elect to separately trade shares of the Class A Common Stock and Warrants comprising the Units commencing on February 8, 2021. ($500.0M proceeds)

8-K filing: MedTech Acquisition Corporation consummated its initial public offering of 25,000,000 units at $10.00 per unit, generating gross proceeds of $250,000,000, and completed a private sale of 4,933,333 warrants to MedTech Acquisition Sponsor LLC for $7,400,000. ($257.4M proceeds)

8-K filing: MedTech Acquisition Corporation consummated its initial public offering of 250,000,000 units at $10.00 per unit, generating gross proceeds of $250,000,000, and completed a private sale of 4,933,333 warrants to the Sponsor at $1.50 per warrant, generating gross proceeds of $7,400,000. ($257.4M proceeds)

S-1/A filing: MedTech Acquisition Corporation is offering 20,000,000 units at $10.00 per unit, with each unit consisting of one share of Class A common stock and one-third of one redeemable warrant.

S-1 filing: MedTech Acquisition Corporation is offering 20,000,000 units at $10.00 per unit, each unit consisting of one share of Class A common stock and one-third of one redeemable warrant, in an initial public offering.